慢性嗜酸性粒细胞白血病中新发现JAK1激活突变
本文报道一例初诊为不明意义高嗜酸性粒细胞增多症的患者,经髓系NGS检测发现新的体细胞JAK1假激酶域突变R629_S632delinsSA,功能研究证实该突变导致Ba/F3细胞不依赖生长因子生长并激活JAK-STAT通路,芦可替尼可逆转上述效应。该突变是首个与克隆性嗜酸性肿瘤相关的JAK1体细胞突变。
要点
- 髓系NGS可将部分不明意义高嗜酸性粒细胞增多症重新归类为克隆性嗜酸性肿瘤。
- 新发现的JAK1 R629_S632delinsSA突变可激活JAK-STAT通路并导致细胞因子非依赖生长。
- JAK1/JAK2抑制剂芦可替尼可逆转该突变所致的功能效应。
核心结论
- R629_S632delinsSA是首个与克隆性嗜酸性肿瘤相关的JAK1体细胞突变,提示JAK-STAT通路在嗜酸性粒细胞存活中的重要性。
研究设计与样本
- 病例报告:一例高嗜酸性粒细胞增多症患者,初始突变被归类为意义未明变异,后经功能研究验证。
主要发现
- 该JAK1假激酶域突变使Ba/F3细胞在体外不依赖生长因子生长,并激活JAK-STAT通路。
- 芦可替尼可消除该突变导致的生长因子非依赖生长和JAK-STAT通路激活。
关键数值与推荐
- 高嗜酸性粒细胞增多症定义为持续性嗜酸性粒细胞>1.5 × 10^9/L。
- 高嗜酸性粒细胞增多症分为克隆性或肿瘤性(HEN)、继发性/反应性(HER)及不明意义(HEUS)。
临床怎么用
- 对不明意义高嗜酸性粒细胞增多症患者可考虑髓系NGS检测以识别克隆性突变。
- 携带JAK1激活突变者可能对芦可替尼等JAK抑制剂治疗敏感。
局限性
- 本文为单例病例报告,结论需在更大样本中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hypereosinophilia (HE) has been defined as persistent eosinophilia >1.5 × 109/L; it is broadly divided into primary HE (clonal or neoplastic; HEN), secondary/reactive HE (HER), or HE of undetermined significance (HEUS) when no cause is identified. The use of myeloid next-generation sequencing (NGS) panels has led to the detection of several mutations in patients previously diagnosed with HEUS, reassigning some patients to the category of HEN, specifically the World Health Organization category of chronic eosinophilic leukemia, not otherwise specified (CEL, NOS). Here, we describe a novel somatic JAK1 pseudokinase domain mutation (R629_S632delinsSA) in a patient with HE that had initially been characterized as a variant of uncertain significance. We performed functional studies that demonstrated that this mutation results in growth factor independence of Ba/F3 cells in vitro and activation of the JAK-STAT pathway. These effects were abrogated by the JAK1/JAK2 inhibitor ruxolitinib. R629_S632delinsSA is the first known somatic mutation in JAK1 linked to a clonal eosinophilic neoplasm, and highlights the importance of the JAK-STAT pathway in eosinophil survival.
引用
- Shomali W, Damnernsawad A, Theparee T, et al. A novel activating JAK1 mutation in chronic eosinophilic leukemia. Blood Adv. 2021. PMID: 34496019. doi:10.1182/bloodadvances.2021004237
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。